November 2024's Rising Stars: Penny Stocks To Watch

As global markets navigate a busy earnings season and mixed economic signals, investors are keenly observing the shifting landscape. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to capture interest due to their potential for growth at lower price points. While the term may seem outdated, these stocks can offer significant opportunities when backed by strong financials and clear growth trajectories.

Top 10 Penny Stocks

Name	Share Price	Market Cap	Financial Health Rating
BP Plastics Holding Bhd (KLSE:BPPLAS)	MYR1.24	MYR343.4M	★★★★★★
Lever Style (SEHK:1346)	HK$0.83	HK$539.57M	★★★★★★
Rexit Berhad (KLSE:REXIT)	MYR0.785	MYR135.97M	★★★★★★
DXN Holdings Bhd (KLSE:DXN)	MYR0.49	MYR2.56B	★★★★★★
Embark Early Education (ASX:EVO)	A$0.755	A$139.45M	★★★★☆☆
Hil Industries Berhad (KLSE:HIL)	MYR0.88	MYR295.43M	★★★★★★
FRP Advisory Group (AIM:FRP)	£1.455	£356.81M	★★★★★★
Wellcall Holdings Berhad (KLSE:WELLCAL)	MYR1.53	MYR761.86M	★★★★★★
Kelington Group Berhad (KLSE:KGB)	MYR3.00	MYR2.14B	★★★★★☆
Next 15 Group (AIM:NFG)	£3.865	£384.4M	★★★★☆☆

Click here to see the full list of 5,767 stocks from our Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

Sichuan Shengda Forestry Industry (SZSE:002259)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Sichuan Shengda Forestry Industry Co., Ltd is involved in the exploration, development, and production of liquefied natural gas (LNG) in China with a market cap of CN¥1.97 billion.

Operations: Sichuan Shengda Forestry Industry Co., Ltd has not reported any specific revenue segments.

Market Cap: CN¥1.97B

Sichuan Shengda Forestry Industry Co., Ltd, with a market cap of CN¥1.97 billion, reported sales of CN¥509.49 million for the nine months ended September 30, 2024, down from the previous year and resulting in a net loss of CN¥20.31 million. Despite being unprofitable, the company has reduced losses over five years and maintains a positive cash flow with sufficient runway for over three years if stable growth continues. However, its short-term assets do not cover long-term liabilities despite exceeding short-term ones. The board is experienced but debt levels have increased significantly over time.

• Click here to discover the nuances of Sichuan Shengda Forestry Industry with our detailed analytical financial health report.
• Review our historical performance report to gain insights into Sichuan Shengda Forestry Industry's track record.

Suzhou Goldengreen Technologies (SZSE:002808)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Suzhou Goldengreen Technologies Ltd. and its subsidiaries focus on the research, development, manufacturing, and sale of laser organic photo-conductor drum products in China with a market cap of CN¥803.71 million.

Operations: Suzhou Goldengreen Technologies Ltd. has not reported any specific revenue segments.

Market Cap: CN¥803.71M

Suzhou Goldengreen Technologies Ltd., with a market cap of CN¥803.71 million, reported sales of CN¥115.67 million for the nine months ended September 30, 2024, showing growth from the previous year despite remaining unprofitable with a net loss of CN¥17.05 million. The company has more cash than total debt and its short-term assets cover both short- and long-term liabilities, indicating financial stability in liquidity management. However, it faces challenges with a negative return on equity and increased losses over five years at an annual rate of 32.1%. The experienced management team offers some strategic stability amidst these challenges.

• Navigate through the intricacies of Suzhou Goldengreen Technologies with our comprehensive balance sheet health report here.
• Assess Suzhou Goldengreen Technologies' previous results with our detailed historical performance reports.

Tiansheng Pharmaceutical Group (SZSE:002872)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Tiansheng Pharmaceutical Group Co., Ltd. is involved in pharmaceutical manufacturing and distribution, with a market cap of CN¥1.44 billion.

Operations: Tiansheng Pharmaceutical Group Co., Ltd. has not reported any specific revenue segments.

Market Cap: CN¥1.44B

Tiansheng Pharmaceutical Group, with a market cap of CN¥1.44 billion, reported sales of CN¥402.36 million for the nine months ended September 30, 2024, slightly down from the previous year. Despite being unprofitable with a net loss of CN¥36.35 million, the company has reduced its losses significantly compared to last year and over five years at an annual rate of 31.5%. The firm maintains financial stability with short-term assets exceeding both short- and long-term liabilities and a satisfactory net debt to equity ratio of 5.2%. Its experienced board and management team provide strategic guidance amidst ongoing challenges in profitability.

• Click to explore a detailed breakdown of our findings in Tiansheng Pharmaceutical Group's financial health report.
• Gain insights into Tiansheng Pharmaceutical Group's historical outcomes by reviewing our past performance report.

Summing It All Up

• Unlock our comprehensive list of 5,767 Penny Stocks by clicking here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com